Evidence map›Paper›PMID 41754072›Full record

ReviewNutrients2026

Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives.

Yandong Li, Linlin Du, Mengyuan Wang, Xingyu He, Zongsuo Liang, Jingling Liu

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yandong LiSchool of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang 712046, China.
Linlin DuCollege of Sciences, Northwest A&F University, Xianyang 712100, China.
Mengyuan WangSchool of Life Science and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Xingyu HeCollege of Sciences, Northwest A&F University, Xianyang 712100, China.
Zongsuo LiangSchool of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang 712046, China.
Jingling LiuCollege of Sciences, Northwest A&F University, Xianyang 712100, China.

Funding

National Key Research and development programme-Modernization of traditional Chinese medicine 2024YFC3506402
6 · The paper itself

Abstract

backgroundCognitive disorders are a class of neurological diseases characterized by declines in cognitive function, imposing a heavy physical and mental burden on middle-aged and elderly individuals. Since the underlying mechanisms of cognitive disorders are not yet fully understood, and different types of cognitive disorders may involve distinct mechanisms, the development of drugs with multi-target therapeutic and preventive effects is of great significance. Currently approved drugs for Alzheimer's disease, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, show limited efficacy and poor prognosis, highlighting the urgent need for safe and effective alternative treatments.

methodsPlant-derived polysaccharides (PDPs) possess antioxidant, anti-inflammatory, neuroprotective, and immunomodulatory activities, and polysaccharides derived from traditional Chinese medicine, in particular, show great potential for treating cognitive disorders. In recent years, interventions with plant polysaccharides that modulate the gut microbiota to affect the "gut-brain axis" and improve cognitive function have become an emerging research focus. Clinical evidence has also increasingly supported the beneficial effects of polysaccharides on cognitive disorders. Therefore, this study focuses on plant polysaccharides in the intervention of cognitive disorder-related diseases, including both in vivo and in vitro experiments, and summarizes existing findings according to different mechanisms of action. RESULTS AND

conclusionsRelevant clinical reports are incorporated to provide a theoretical basis and strong support for the development of polysaccharide-based interventions and new drug development for cognitive disorders.

Indexed as

Cognition DisordersPolysaccharidesAnimalsAntioxidantsBrainCognitionGastrointestinal MicrobiomeHumansNeuroprotective AgentsAntioxidantsNeuroprotective AgentsPolysaccharidesclinical translation & RCTscognitive impairment and neurodegenerationgut–brain axis and microbiotaneuroprotectionplant-derived polysaccharides (PDPs)protein aggregation & apoptosis

Identifiers

PMID41754072
PMCPMC12942708

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.